Loading
A phase 1/2 trial of Elranatamab, Mezigdomide, Dexamethasone in multiple myeloma, run by Celgene, now recruiting.
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06988488 by Celgene, with 62 participants planned, started 2025-10-07 and due to reach its primary completion in 2027-05-31. Interventions recorded: Elranatamab, Mezigdomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Elranatamab, Dexamethasone, Relapsed or refractory multiple myeloma, PROTACs & molecular glues (targeted protein degradation).
Shares Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma, PROTACs & molecular glues (targeted protein degradation).
Shares Elranatamab, PROTACs & molecular glues (targeted protein degradation), T-cell engagers (bispecific), Multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.